Codis expands UK manufacturing with groundbreaking spray dryer
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
The first of four planned modules at the new plant is expected to come online by summer 2026
The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant
The facility is expected to become operational by FY2028-29
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
This transaction fundamentally strengthens Scinai's CDMO platform
Subscribe To Our Newsletter & Stay Updated